Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating safety, tolerability, and pharmacokinetics of APN1125 in schizophrenia. The study status is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• APN1125

Snippet

Sponsor: CoMentis | Conditions: Schizophrenia | Phase 1, Phase 2 | Status: SUSPENDED